Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 156

1.

Geographical differences in first acquisition of Pseudomonas aeruginosa in cystic fibrosis.

Ranganathan SC, Skoric B, Ramsay KA, Carzino R, Gibson AM, Hart E, Harrison J, Bell SC, Kidd TJ; Australian Respiratory Early Surveillance Team for Cystic Fibrosis (AREST-CF) *.

Ann Am Thorac Soc. 2013 Apr;10(2):108-14. doi: 10.1513/AnnalsATS.201209-077OC.

PMID:
23607838
2.

Comprehensive analysis of risk factors for acquisition of Pseudomonas aeruginosa in young children with cystic fibrosis.

Kosorok MR, Jalaluddin M, Farrell PM, Shen G, Colby CE, Laxova A, Rock MJ, Splaingard M.

Pediatr Pulmonol. 1998 Aug;26(2):81-8.

PMID:
9727757
3.

Acquisition of Pseudomonas aeruginosa in children with cystic fibrosis.

Farrell PM, Shen G, Splaingard M, Colby CE, Laxova A, Kosorok MR, Rock MJ, Mischler EH.

Pediatrics. 1997 Nov;100(5):E2.

PMID:
9346996
4.

Season is associated with Pseudomonas aeruginosa acquisition in young children with cystic fibrosis.

Psoter KJ, De Roos AJ, Wakefield J, Mayer J, Rosenfeld M.

Clin Microbiol Infect. 2013 Nov;19(11):E483-9. doi: 10.1111/1469-0691.12272. Epub 2013 Jun 25.

5.

Pseudomonas aeruginosa genotypes acquired by children with cystic fibrosis by age 5-years.

Kidd TJ, Ramsay KA, Vidmar S, Carlin JB, Bell SC, Wainwright CE, Grimwood K; ACFBAL Study Investigators.

J Cyst Fibros. 2015 May;14(3):361-9. doi: 10.1016/j.jcf.2014.12.007. Epub 2015 Jan 3.

6.

Early cystic fibrosis lung disease detected by bronchoalveolar lavage and lung clearance index.

Belessis Y, Dixon B, Hawkins G, Pereira J, Peat J, MacDonald R, Field P, Numa A, Morton J, Lui K, Jaffe A.

Am J Respir Crit Care Med. 2012 Apr 15;185(8):862-73. doi: 10.1164/rccm.201109-1631OC. Epub 2012 Feb 9.

PMID:
22323305
7.

Fine particulate matter exposure and initial Pseudomonas aeruginosa acquisition in cystic fibrosis.

Psoter KJ, De Roos AJ, Mayer JD, Kaufman JD, Wakefield J, Rosenfeld M.

Ann Am Thorac Soc. 2015 Mar;12(3):385-91. doi: 10.1513/AnnalsATS.201408-400OC.

PMID:
25594356
8.

Risk factors for initial acquisition of Pseudomonas aeruginosa in children with cystic fibrosis identified by newborn screening.

Maselli JH, Sontag MK, Norris JM, MacKenzie T, Wagener JS, Accurso FJ.

Pediatr Pulmonol. 2003 Apr;35(4):257-62.

PMID:
12629621
9.
10.

Type 3 secretion system effector genotype and secretion phenotype of longitudinally collected Pseudomonas aeruginosa isolates from young children diagnosed with cystic fibrosis following newborn screening.

Hu H, Harmer C, Anuj S, Wainwright CE, Manos J, Cheney J, Harbour C, Zablotska I, Turnbull L, Whitchurch CB, Grimwood K, Rose B; FBAL study investigators.

Clin Microbiol Infect. 2013 Mar;19(3):266-72. doi: 10.1111/j.1469-0691.2012.03770.x. Epub 2012 Feb 13.

11.

Impact of inhaled corticosteroids on the risk of early Pseudomonas aeruginosa acquisition in cystic fibrosis.

Minicucci L, Severi G, Cresta L, Giannattasio A, Lorini R, Haupt R.

Acta Paediatr. 2003 Jun;92(6):684-7.

PMID:
12856978
12.

Acceleration of lung disease in children with cystic fibrosis after Pseudomonas aeruginosa acquisition.

Kosorok MR, Zeng L, West SE, Rock MJ, Splaingard ML, Laxova A, Green CG, Collins J, Farrell PM.

Pediatr Pulmonol. 2001 Oct;32(4):277-87.

PMID:
11568988
13.

Virulence factor expression patterns in Pseudomonas aeruginosa strains from infants with cystic fibrosis.

Manos J, Hu H, Rose BR, Wainwright CE, Zablotska IB, Cheney J, Turnbull L, Whitchurch CB, Grimwood K, Harmer C, Anuj SN, Harbour C; ACFBAL study group.

Eur J Clin Microbiol Infect Dis. 2013 Dec;32(12):1583-92. doi: 10.1007/s10096-013-1916-7. Epub 2013 Jul 7.

PMID:
23832143
14.

Longitudinal assessment of Pseudomonas aeruginosa in young children with cystic fibrosis.

Burns JL, Gibson RL, McNamara S, Yim D, Emerson J, Rosenfeld M, Hiatt P, McCoy K, Castile R, Smith AL, Ramsey BW.

J Infect Dis. 2001 Feb 1;183(3):444-52. Epub 2000 Dec 27.

PMID:
11133376
15.

Concordant genotype of upper and lower airways P aeruginosa and S aureus isolates in cystic fibrosis.

Mainz JG, Naehrlich L, Schien M, Käding M, Schiller I, Mayr S, Schneider G, Wiedemann B, Wiehlmann L, Cramer N, Pfister W, Kahl BC, Beck JF, Tümmler B.

Thorax. 2009 Jun;64(6):535-40. doi: 10.1136/thx.2008.104711. Epub 2009 Mar 11.

PMID:
19282318
16.

The social network of cystic fibrosis centre care and shared Pseudomonas aeruginosa strain infection: a cross-sectional analysis.

Kidd TJ, Soares Magalhães RJ, Paynter S, Bell SC; ACPinCF Investigator Group.

Lancet Respir Med. 2015 Aug;3(8):640-50. doi: 10.1016/S2213-2600(15)00228-3. Epub 2015 Jul 22.

PMID:
26208994
17.

Acquisition and eradication of P. aeruginosa in young children with cystic fibrosis.

Douglas TA, Brennan S, Gard S, Berry L, Gangell C, Stick SM, Clements BS, Sly PD.

Eur Respir J. 2009 Feb;33(2):305-11. doi: 10.1183/09031936.00043108. Epub 2008 Nov 14.

18.

Clinical outcome after early Pseudomonas aeruginosa infection in cystic fibrosis.

Nixon GM, Armstrong DS, Carzino R, Carlin JB, Olinsky A, Robertson CF, Grimwood K.

J Pediatr. 2001 May;138(5):699-704.

PMID:
11343046
19.

Effect of bronchoalveolar lavage-directed therapy on Pseudomonas aeruginosa infection and structural lung injury in children with cystic fibrosis: a randomized trial.

Wainwright CE, Vidmar S, Armstrong DS, Byrnes CA, Carlin JB, Cheney J, Cooper PJ, Grimwood K, Moodie M, Robertson CF, Tiddens HA; ACFBAL Study Investigators.

JAMA. 2011 Jul 13;306(2):163-71. doi: 10.1001/jama.2011.954.

PMID:
21750293
20.

Early bacteriologic, immunologic, and clinical courses of young infants with cystic fibrosis identified by neonatal screening.

Abman SH, Ogle JW, Harbeck RJ, Butler-Simon N, Hammond KB, Accurso FJ.

J Pediatr. 1991 Aug;119(2):211-7.

PMID:
1907318

Supplemental Content

Support Center